Premalux AB
Sweden
News
OHB-607 Approaching a Key Clinical Milestone
October 2026
The development of OHB-607 has reached an important and exciting stage following the successful completion of patient enrollment in the global Phase 2b pivotal FOOTPRINTS study in June 2026.
With 352 extremely premature infants enrolled, the study represents a significant milestone in the clinical development of OHB-607, a potential first-in-class treatment addressing a major unmet medical need.
The program is now progressing towards one of its most important milestones: the reporting of topline clinical results.
According to the latest publicly communicated timeline from Chiesi Group and Oakhill bio Holdings, topline results are anticipated around the turn of the year. The precise timing remains dependent on the completion of clinical data collection, validation and analysis.
Premalux views the progress of the OHB-607 development program as an encouraging step forward and looks forward to the upcoming results, which will provide important insights into the treatment's clinical potential.
Further updates will be communicated as new information becomes publicly available.
Click here to read more in Oak Hill Bio Holdings's press release.
About Premalux
Premalux AB is a Swedish company involved in early-stage research within neonatal medicine, focused on addressing complications associated with extremely premature birth. The company's work contributed to foundational research efforts that led to the development of the therapeutic candidate now known as OHB-607, currently in clinical research phase.
Premalux holds certain intellectual property rights related to this work, including rights to future milestone payments and royalties in the event of regulatory approval of OHB-607.
The company's current role is primarily administrative, including oversight of historical agreements and ensuring compliance with contractual obligations related to its intellectual property. The continued clinical development and potential commercialization of OHB-607 are conducted by external pharmaceutical organizations.
The OHB-607 Program
Every year, hundreds of thousands of infants worldwide are born extremely prematurely and, as a result, suffer from severe complications in their lungs, brain, and eyes — complications that can hinder long-term development and quality of life.
OHB-607 (formerly TAK-607) is a proprietary, recombinant version of insulin-like growth factor 1 (IGF-1) combined with its binding protein IGFBP-3. It represents a straightforward replacement therapy approach.
Mothers are the primary source of IGF-1 for the developing fetus, with the fetus producing very little of its own until approximately 30 weeks of gestational age. At birth, extremely premature infants — born at less than 28 weeks — have low levels of IGF-1, which are associated with greater complication rates.
OHB-607 is designed to make up for the IGF-1 deficiency that occurs in extremely preterm birth, thereby helping to promote continued development and maturation of vital organs and the vasculature that supports them.
According to publicly available information, OHB-607 has shown a statistically significant improvement in preventing severe bronchopulmonary dysplasia (BPD) and a positive trend in reducing intraventricular hemorrhage in a Phase 2a clinical trial. The therapy is now being evaluated in a Phase 2b study called Footprints, conducted by Oak Hill Bio in collaboration with Chiesi Group.
Premalux AB holds certain intellectual property rights related to the early development of this therapy, including rights to future milestone payments and royalties contingent upon potential regulatory approval. Premalux is not responsible for the ongoing clinical development or clinical trials.
For information regarding clinical trials, please refer to clinicaltrials.gov or the organizations responsible for the program.
Information Policy
publicly available verified through credible sources already disclosed by the organizations responsible for clinical development
Information that may not be shared publicly includes, but is not limited to:
confidential contractual terms
proprietary research data
unpublished clinical data
regulatory communications
internal strategy or development plans
information received under confidentiality agreements
All individuals within the Premalux organization are bound by confidentiality in the handling of sensitive information.
Privacy Policy
Premalux AB is committed to protecting your personal privacy. This website does not collect personal data beyond what is required to provide basic functionality.
Any contact inquiries sent to Premalux are handled confidentially and used solely to respond to the inquiry in question.
Premalux does not share personal data with third parties and does not store sensitive information without explicit consent.
For questions regarding how your personal data is handled, please contact us at jacob@testor.se.
Notice of General meeting
There is currently no notice of a general meeting. Information regarding upcoming general meetings will be published here
